Camurus AB

Company Overview

Camurus, a Swedish pharmaceutical business is dedicated to creating and marketing novel, long-acting medications for the treatment of severe and chronic illnesses. Camurus is dedicated to leading the development of cutting-edge medication delivery systems and groundbreaking medical items to enhance the quality of life for people with severe and persistent illnesses. These drugs cover a range of therapeutic areas, including cancer, endocrinology, pain, metabolic disease, and drug addiction.

Camurus has developed two novel platforms for delivery of nanoparticle and nanocrystal drugs. The company’s proprietary FluidCrystal drug delivery technology and its significant R&D know-how are used to develop new pharmaceutical solutions with the potential to be best-in-class.

The Fluid Crystal NP injection nanoparticle delivery system provides a high drug payload in a liquid crystal nanoparticle system. It was developed for intravenous bolus injection and infusion products as well as for subcutaneous injection products. The unique liquid crystal interior with an enormous surface area makes these particles suitable carriers for amphiphilic and lipophilic drug compounds. These are ideally suited for drugs with solubility limitations or for encapsulation of sensitive drug compounds such as peptides and proteins.

The second platform, the Fluid Crystal NP transdermal nanoparticle system, was developed to improve the bioavailability of small molecule drugs and peptides by both facilitating high drug payload and efficient transport across the skin.

Camurus’s strategy is to continue developing drugs to meet the needs of its target disease category areas. At the same time, it will pursue agreements with other companies for use of its technology for inclusion in its drug development and delivery systems. With its headquarters in Lund, Sweden, and larger regional offices in Cambridge, the U.K., Mannheim, Germany, and Sydney, Australia, and Camurus has close to 200 people worldwide.

Financial Highlights (FY 2024)

Company's Business Segments

• Nanoscale Drug-delivery Systems : The company develops and commercializes advanced medicines for severe and chronic diseases, particularly those related to the central nervous system, rare diseases, endocrine disorders, oncology, and supportive care.